Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Faris

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
The American Journal of Medicine|August 9, 2005
Time tells the taleJason E Faris, Cynthia D Brown
Clinical Advances in Hematology & Oncology : H&O|April 16, 2009
Primary mediastinal large B-cell lymphomaJason E Faris, Ann S LaCasce
Current Opinion in Endocrinology, Diabetes, and Obesity|April 21, 2010
Metabolic sequelae associated with androgen deprivation therapy for prostate cancerJason E Faris, Matthew R Smith
Nature Reviews. Clinical Oncology|December 24, 2009
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCCJason E Faris, M Dror Michaelson
Current Treatment Options in Oncology|August 13, 2013
Controversy and consensus on the management of patients with pseudomyxoma peritoneiJason E Faris, David P Ryan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type diseaseJason E Faris, David P Ryan
Journal of Hepato-Biliary-Pancreatic Sciences|February 10, 2012
Targeted therapy for biliary tract cancersJason E Faris, Andrew X Zhu
The Oncologist|September 12, 2013
The controversial role of chemoradiation for patients with locally advanced pancreatic cancerJason E Faris, Jennifer Y Wo
Thyroid : Official Journal of the American Thyroid Association|August 24, 2007
Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case reportJason E Faris, Allan F Moore, Gilbert H Daniels
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal MalignanciesKhaldoun Almhanna, Thea Kalebic, Cristina Cruz, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
The American Journal of Medicine|August 9, 2005
Time tells the taleJason E Faris, Cynthia D Brown
Clinical Advances in Hematology & Oncology : H&O|April 16, 2009
Primary mediastinal large B-cell lymphomaJason E Faris, Ann S LaCasce
Current Opinion in Endocrinology, Diabetes, and Obesity|April 21, 2010
Metabolic sequelae associated with androgen deprivation therapy for prostate cancerJason E Faris, Matthew R Smith
Nature Reviews. Clinical Oncology|December 24, 2009
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCCJason E Faris, M Dror Michaelson
Current Treatment Options in Oncology|August 13, 2013
Controversy and consensus on the management of patients with pseudomyxoma peritoneiJason E Faris, David P Ryan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wild-type diseaseJason E Faris, David P Ryan
Journal of Hepato-Biliary-Pancreatic Sciences|February 10, 2012
Targeted therapy for biliary tract cancersJason E Faris, Andrew X Zhu
The Oncologist|September 12, 2013
The controversial role of chemoradiation for patients with locally advanced pancreatic cancerJason E Faris, Jennifer Y Wo
Thyroid : Official Journal of the American Thyroid Association|August 24, 2007
Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case reportJason E Faris, Allan F Moore, Gilbert H Daniels
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal MalignanciesKhaldoun Almhanna, Thea Kalebic, Cristina Cruz, et al.
Pageof 4